
Sol-Gel Technologies Hits New 52-Week High of $30.98, Surges 3861%
2025-09-22 18:16:34Sol-Gel Technologies achieved a new 52-week high of USD 30.98 on September 19, 2025, reflecting a remarkable performance in the Pharmaceuticals & Biotechnology sector. The company reported a 1574.2% increase in net sales to USD 18.29 million in the first half of the year, despite ongoing losses.
Read MoreIs Sol-Gel Technologies Ltd. technically bullish or bearish?
2025-09-20 19:32:21As of 4 September 2025, the technical trend for Sol-Gel Technologies Ltd. has changed from mildly bullish to bullish. The weekly MACD is bullish, and both the weekly and monthly Bollinger Bands are bullish, indicating positive momentum. However, the monthly RSI is bearish, suggesting some weakness in price strength. The daily moving averages are bullish, supporting the overall positive outlook. Despite the bullish trend, the weekly OBV is mildly bearish, which could indicate some selling pressure. In terms of performance, the stock has significantly outperformed the S&P 500 across multiple periods, with a year-to-date return of 185.64% compared to the S&P 500's 12.22%, and a one-year return of 310.25% versus 17.14%. Overall, the current technical stance is bullish, with strong momentum indicators but some caution due to the bearish monthly RSI....
Read MoreIs Sol-Gel Technologies Ltd. overvalued or undervalued?
2025-09-20 18:08:17As of 10 March 2023, the valuation grade for Sol-Gel Technologies Ltd. moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.00 and an EV to Sales ratio of 0.30, which suggest limited growth potential in relation to its market price. Additionally, the company's negative ROCE of -388.12% and ROE of -64.66% further highlight its struggles in generating returns for shareholders. In comparison to its peers, Sol-Gel Technologies Ltd. has a significantly higher EV to EBITDA ratio of -11.1084 compared to Assembly Biosciences, Inc. at -6.6467 and Societal CDMO, Inc. at 18.7985, indicating that it is not performing well relative to its industry counterparts. The overall financial health and performance metrics suggest that the company is overvalued in the current market context. The...
Read More





